Iqvia Holdings Inc (IQV) Expected to Announce Quarterly Sales of $2.14 Billion

Equities research analysts expect Iqvia Holdings Inc (NYSE:IQV) to post sales of $2.14 billion for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have made estimates for Iqvia’s earnings, with the highest sales estimate coming in at $2.15 billion and the lowest estimate coming in at $2.13 billion. Iqvia posted sales of $1.95 billion in the same quarter last year, which would indicate a positive year over year growth rate of 9.7%. The company is scheduled to announce its next earnings results on Tuesday, February 13th.

On average, analysts expect that Iqvia will report full-year sales of $2.14 billion for the current year, with estimates ranging from $8.02 billion to $8.06 billion. For the next financial year, analysts expect that the firm will report sales of $8.53 billion per share, with estimates ranging from $8.49 billion to $8.61 billion. Zacks’ sales averages are an average based on a survey of analysts that cover Iqvia.

Iqvia (NYSE:IQV) last issued its quarterly earnings results on Thursday, October 26th. The medical research company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.14 by $0.05. Iqvia had a net margin of 0.58% and a return on equity of 12.60%. The business had revenue of $2.02 billion for the quarter, compared to analysts’ expectations of $2.01 billion. During the same quarter last year, the company posted $1.00 earnings per share. The company’s quarterly revenue was up 77.6% compared to the same quarter last year.

A number of brokerages have issued reports on IQV. SunTrust Banks reissued a “hold” rating and issued a $114.00 target price on shares of Iqvia in a report on Friday, November 3rd. Jefferies Group raised their target price on shares of Iqvia from $107.00 to $110.00 and gave the stock a “hold” rating in a report on Monday, October 30th. Zacks Investment Research cut shares of Iqvia from a “buy” rating to a “hold” rating in a report on Friday, November 3rd. Credit Suisse Group reissued an “outperform” rating and issued a $125.00 target price (up previously from $115.00) on shares of Iqvia in a report on Tuesday, October 31st. Finally, Barclays raised their target price on shares of Iqvia from $100.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, October 27th. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $106.94.

In related news, insider James H. Erlinger III sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 18th. The shares were sold at an average price of $100.51, for a total transaction of $1,005,100.00. Following the transaction, the insider now owns 27,340 shares in the company, valued at $2,747,943.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ari Bousbib sold 46,080 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $108.14, for a total transaction of $4,983,091.20. Following the transaction, the insider now owns 1,036,839 shares in the company, valued at approximately $112,123,769.46. The disclosure for this sale can be found here. Insiders sold 8,806,558 shares of company stock worth $898,722,108 in the last 90 days. 6.40% of the stock is owned by company insiders.

Shares of Iqvia (NYSE:IQV) traded down $2.24 during mid-day trading on Friday, hitting $97.28. 1,795,900 shares of the stock traded hands, compared to its average volume of 1,294,333. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 1.29. Iqvia has a twelve month low of $74.80 and a twelve month high of $110.67. The company has a market capitalization of $20,230.00, a PE ratio of 335.45, a price-to-earnings-growth ratio of 1.37 and a beta of 0.61.

TRADEMARK VIOLATION WARNING: “Iqvia Holdings Inc (IQV) Expected to Announce Quarterly Sales of $2.14 Billion” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://ledgergazette.com/2018/01/12/iqvia-holdings-inc-iqv-expected-to-announce-quarterly-sales-of-2-14-billion.html.

Iqvia Company Profile

IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Get a free copy of the Zacks research report on Iqvia (IQV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply